Drugs / RAB001
RAB001
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07652372 | Apr 2026 → Jun 2027 expected | osteoarthritis, knee | ZhongShan LaiBo RuiChen BioMedicine Co.,Ltd. | Enrolling by invitation | No outcome recorded |
| Phase 1 | NCT07545018 | Feb → Jul 2023 | avascular necrosis | ZhongShan LaiBo RuiChen BioMedicine Co.,Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07471880 | Dec 2024 → Oct 2026 expected | secondary avascular necrosis | ZhongShan LaiBo RuiChen BioMedicine Co.,Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RAB001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07471880 ↗ |
| Known as | LLP2A-Ale | “RAB001（LLP2A-Ale） in Healthy Subjects” NCT07545018 ↗ |
| Known as | LLP2A-Alendronate | “A Phase II Trial of RAB001 (LLP2A-Alendronate) for Steroid-Induced Early-Stage Osteonecrosis of the Femoral Head” NCT07471880 ↗ |
| Route | Intravenous | “Intravenous infusion RAB001 1200μg/kg” NCT07471880 ↗ |